On Monday, the fascinating conclusion to a lengthy court battle between Swiss drugmaker Novartis (NVS +0.21%) and the Supreme Court of India was revealed. The court ruled that Novartis' top-selling blockbuster drug Glivec (which is branded as Gleevec in the U.S.) should not be granted patent protection, which means that generic competitors can continue manufacturing their own versions of the drug in India. As the debate continues over the long-term implications of this controversial decision, investors are wondering how this ruling actually impacts Novartis' sales. In the following video, health care analyst Max Macaluso discusses the effect of this decision on Novartis' top line.
Should Novartis Investors Worry About This Supreme Court Ruling?
By Max Macaluso – Apr 3, 2013 at 6:30PM
NYSE: NVS
Novartis
Market Cap
$249B
Today's Change
(0.21%) $0.27
Current Price
$131.61
Price as of October 22, 2025 at 10:14 AM ET
How will this ruling on Glivec's patent affect Novartis' revenue this year?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo